REACH
2 March 2022
Nuformix plc
("Nuformix" or the "Company")
Appointment of Dr Dan Gooding as Consultant
Nuformix plc (LSE: NFX), the pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Dr Dan Gooding as a consultant to the Company. Dr Gooding was a co-founder and ex-CEO of Nuformix and instigated the Company's NXP002 programme as an inhaled therapy for the treatment of Idiopathic Pulmonary Fibrosis ("IPF").
Commenting on his appointment, Dr Gooding said: "I am a strong believer in the potential of NXP002 as an inhaled therapy for the treatment of IPF. The recent positive pre-clinical data further cements this belief and I am delighted to be able to support the Company in its development and commercialisation activities for the NXP002 programme. My detailed knowledge of previous development strategies, commercial discussions and continued commitment to the success of the project and the Company will now be brought to bear in a formal way, alongside the Nuformix team, for the benefit of the NXP002 programme and the Company's shareholders."
Nuformix's Executive Chairman, Dr Alastair Riddell, said: " The recent positive pre-clinical studies on NXP002 warrant the progression of further product development and commercial discussions with licensing partners. Dr Gooding brings significant corporate history and experience to the table which will help facilitate these activities.
"Now the Company is able to invest in the formal development of NXP002, our objective is to progress NXP002 through a series of value-inflexion points prior to out-licensing. We look forward to announcing further results from our ongoing pre-clinical studies on NXP002 in the near future.
"Furthermore, our search for a new CEO is progressing well and I look forward to announcing an appointment in due course."
Enquiries:
| Nuformix plc | |
| Dr Alastair Riddell, Executive Chairman
| Via IFC Advisory |
| Stanford Capital Partners Limited | |
| Tom Price / Patrick Claridge (Corporate Finance) | +44 (0) 20 3650 3650 |
| John Howes (Corporate Broking) | +44 (0) 20 3650 3652
|
| IFC Advisory Limited | |
| Tim Metcalfe Zach Cohen | +44 (0) 20 3934 6630 |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
About NXP002
NXP002 is a new form of tranilast being developed as an inhaled product for the treatment of Idiopathic Pulmonary Fibrosis, a devastating lung disease with a high mortality rate. The IPF market reached a value of £2bn in 2021 and is forecast to grow to £6.6bn by 2027. Novel therapeutic interventions are required as approved therapies are limited to slowing disease progression. NXP002 is being developed for delivery direct to the lungs by inhalation, a new route of administration for this drug, uniquely enabled by Nuformix technology protected by internationally granted patents. The inhalation route is a well-known strategy for treatment of lung diseases to yield greater efficacy and reduce systemic side-effects compared to oral treatment.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.